Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

2 results
12:00 AM, Nov 16, 2009  |  BC Week In Review | Clinical News  |  Regulatory

Brivudine regulatory update

Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for RESprotect's RP101
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif.   RESprotect GmbH , Dresden, Germany   Product: Brivudine
12:00 AM, Feb 11, 2008  |  BC Week In Review | Clinical News  |  Regulatory

BVdU regulatory update

FDA granted Orphan Drug designation for RP101 for use as an adjunct to treat pancreatic cancer …
Phase II testing to treat advanced pancreatic cancer. SciClone licensed U.S. and Canadian rights to RP101
Inc. (OTCBB:AVTO), Los Angeles, Calif.   SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), San Mateo, Calif.   Product: BVdU